
Opinion|Videos|May 7, 2025
Exploring the Impact of Bronchiectasis Exacerbations
Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis exacerbations, leading to increased cough, phlegm, fatigue, and hemoptysis.
Advertisement
Episodes in this series

Clinical Brief: Causes and Management of Bronchiectasis Exacerbations
Main Discussion Topics
- Exacerbations are commonly triggered by bacterial infections, viral etiologies, and environmental factors.
- Impaired mucosal clearance significantly contributes to recurrent exacerbations.
- Management approaches include multiple modalities targeting different aspects of the disease.
Key Points for Physicians
- Monitor for increased cough, phlegm, fatigue, and hemoptysis as signs of exacerbation.
- Treatment options include:
- Oral, intravenous, or inhaled antibiotics based on severity
- Airway clearance devices (Vest, oscillating positive expiratory pressure devices like AerobikA/Acapella)
- Breathing techniques and mechanical assistance
- Anti-inflammatory approaches (DPP1 inhibitors, inhaled corticosteroids for eosinophilic phenotype)
- Consider surgical intervention for refractory cases
Notable Insights
Comprehensive management must address multiple dimensions, including infection control, inflammation reduction, mucus clearance enhancement, and hydration.
Clinical Significance
Effective bronchiectasis exacerbation management requires targeted multimodal therapies addressing both immediate symptoms and underlying mechanisms to prevent recurrence.
Advertisement
Related to this article

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.

From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
3
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
4
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
5

